Tableau I.
Molécules PROTAC en essai clinique pour le traitement de divers cancers. AR : Androgen Receptor, ER: Estrogen Receptor, BCL-xl : B-cell lymphoma-extra large, BRD9 : Bromodomain-containing protein 9, IRAK4 : interleukin-1 receptor-associated kinase 4, STAT3 : signal transducer and activator of transcription 3, BTK : Burton’s tyrosine kinase.
| PROTAC | Cible | Type de cancer ciblé | Phase clinique |
|---|---|---|---|
| ARV-110 | AR | Cancer de prostate | II |
| ARV-471 | ER | Cancer de sein | II |
| AC682 | ER | Cancer de sein | I |
| ARV-766 | AR | Cancer de prostate | I |
| CC-94676 | AR | Cancer de prostate | I |
| DT2216 | BCL-xl | Hémopathies malignes et tumeurs solides récidivantes/réfractaires | I |
| FHD-609 | BRD9 | Sarcome synovial | I |
| KT-413 | IRAK4 | Lymphome diffus à grandes cellules B (mutant MYD88) | I |
| KT-333 | STAT3 | Hémopathies malignes et tumeurs solides récidivantes/réfractaires | I |
| NX-2127 | BTK | Lymphome à cellules B | I |
| NX-5948 | BTK | Lymphome à cellules B | I |
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.